Label Changes for:
Avastin (bevacizumab) Solution for intravenous infusion
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011
- include additional information regarding ocular and systemic adverse events following unapproved intravitreal use for treatment of various ocular disorders.